EDGEMOND JAMES bought UTHR
March 15, 2023 · Form 4 insider transaction
EDGEMOND JAMES bought 9,098 shares of United Therapeutics Corporation at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 1079 days after the transaction.
Footnotes
These performance-based restricted stock units were initially awarded on March 15, 2023, subject to a three-year performance condition tied to average revenue growth during 2023-2025, which was determined on February 25, 2026. The number of restricted stock units reported represents the number of restricted stock units earned based on performance, all of which will vest on March 15, 2026.; Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.; Not applicable as restricted stock units do not have an expiration date.